# Acetazolamide Efficacy in Ataxia in PMM2-CDG

> **NCT04679389** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 25 (actual)

## Conditions studied

- Pmm2-CDG
- CDG1A

## Interventions

- **DRUG:** Placebo
- **DRUG:** Acetazolamide

## Key facts

- **NCT ID:** NCT04679389
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679389, "Acetazolamide Efficacy in Ataxia in PMM2-CDG". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04679389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*